Otonomy to Host Investor and Analyst Day on October 7, 2015
September 30 2015 - 7:30AM
Otonomy, Inc. (Nasdaq:OTIC) will host an Investor and Analyst Day
on Wednesday, October 7, 2015, from 8:30 a.m. to 11:30 a.m. EDT
(5:30 a.m. to 8:30 a.m. PDT) in New York City. David A. Weber,
Ph.D., president and chief executive officer, and other members of
the Otonomy management team will provide a comprehensive update of
commercialization plans for AuriPro™ in patients undergoing ear
tube surgery, a review of the Phase 3 clinical trial program for
OTO-104 in Ménière's disease, and an introduction to the OTO-311
program for tinnitus. In addition, notable otolaryngology experts
will discuss their perspective on these otic disorders and
Otonomy's pipeline of drug candidates.
Interested parties may access a live audio webcast and slides of
the presentations on the investor section of Otonomy's website at
www.otonomy.com beginning at 8:30 a.m. EDT. An archive of the
webcast will be available shortly after the event and can be viewed
at the same link for a limited time.
About Otonomy
Otonomy is a clinical-stage biopharmaceutical company focused on
the development and commercialization of innovative therapeutics
for diseases and disorders of the ear. Otonomy's proprietary
technology provides sustained exposure of drugs to the ear
following a single administration. Otonomy has three product
candidates in development. AuriPro™ is an antibiotic that has
completed Phase 3 clinical trials in pediatric patients with middle
ear effusion at the time of tympanostomy tube placement surgery,
and the FDA has assigned a PDUFA action date of December 25, 2015
for the company's New Drug Application. OTO-104 is a steroid that
has completed a Phase 2b clinical trial in 154 patients with
Ménière's disease. Based on these results, Otonomy intends to
initiate two parallel Phase 3 trials for OTO-104 in Ménière's
disease patients with at least one trial initiated by the end of
2015. OTO-311 is an NMDA receptor antagonist in development as a
treatment for tinnitus. For additional information please visit
www.otonomy.com.
Cautionary Note Regarding Forward Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements generally relate to future events
or Otonomy's future financial or operating performance.
Forward-looking statements in this press release include, but are
not limited to, the initiation, timing and design of Otonomy's
Phase 3 clinical trials with OTO-104 and the timing of the launch
of AuriPro™. Otonomy's expectations regarding these matters may not
materialize, and actual results in future periods are subject to
risks and uncertainties. Actual results may differ materially from
those indicated by these forward-looking statements as a result of
these risks and uncertainties, including but not limited to: the
uncertainties inherent in the clinical drug development process,
including, without limitation, Otonomy's ability to adequately
demonstrate the safety and efficacy of its product candidates, the
preclinical and clinical results for its product candidates, which
may not support further development of product candidates, and
challenges related to patient enrollment in clinical trials;
Otonomy's ability to obtain regulatory approval for its product
candidates; side effects or adverse events associated with
Otonomy's product candidates; developments related to competitors
and the industry; Otonomy's dependence on third parties to conduct
preclinical studies and clinical trials; Otonomy's dependence on
third parties for the manufacture of products; Otonomy's dependence
on a small number of suppliers for raw materials; Otonomy's ability
to protect its intellectual property related to product candidates
in the United States and throughout the world; and other risks.
Otonomy undertakes no obligation to update any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by applicable law.
CONTACT: MEDIA CONTACT:
Canale Communications
Heidi Chokeir, Ph.D.
Senior Vice President
(619) 849-5377
heidi@canalecomm.com
INVESTOR CONTACT:
Westwicke Partners, LLC
Robert H. Uhl
Managing Director
(858) 356-5932
robert.uhl@westwicke.com
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Jul 2023 to Jul 2024